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The success of influenza vaccination depends
largely on the antigenic match between the in-
fluenza vaccine strains and the virus strains ac-
tually circulating during the season. In the past,
this match has proved to be satisfactory in most
seasons. In the 1997/1998 season, however,
hemagglutination inhibition (HI) assays with fer-
ret antisera indicated a considerable mismatch
between the H3N2 vaccine component and the
most prevalent epidemic influenza A(H3N2) vi-
rus. The results from antigenic analyses using
pre- and postvaccination serum samples from
volunteers of various ages, including residents
of nursing homes who were more than 60 years
of age, were in good agreement with the results
obtained with ferret antisera. Homologous se-
rum antibody responses to the H3N2 vaccine
component as well as the cross-reactivity of the
induced antibodies to the epidemic H3N2 strain,
declined with increasing age of the vaccinees.
As a consequence of these two effects, 84% of
the vaccinees over 75 years of age did not de-
velop HI antibody titers $ 40 against the major
H3N2 virus variant of 1997/1998, suggesting that
they were not protected against infection with
this virus variant. These findings support the
current policy of the World Health Organization
(WHO), which is to base worldwide influenza vi-
rus surveillance on results predominantly ob-
tained by antigenic analyses of influenza virus
isolates with ferret antisera in HI tests. If an an-
tigenic mismatch is observed, the protective ef-
ficacy of the vaccine, especially for the elderly,
may be insufficient. The observations also sup-
port the current policy to include the elderly in
serologic efficacy trials. J. Med. Virol. 61:94–99,
2000. © 2000 Wiley-Liss, Inc.
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INTRODUCTION
The cornerstone for the prevention of influenza is
annual vaccination with inactivated virus vaccines
[Betts, 1995]. Because of the frequently occurring an-
tigenic changes, the World Health Organization
(WHO) coordinates a worldwide surveillance of influ-
enza virus strains, characterized conventionally by
their reactivity in hemagglutination inhibition (HI) as-
says with ferret antisera. Based on the results of these
assays, the vaccine formulation is adapted yearly to
include those virus variants that are most likely to cir-
culate in the coming season. The effectiveness of this
prophylaxis largely depends on the match between the
vaccine strains and the circulating viruses [Mullooly et
al., 1993]. This match has been fairly accurate over the
past decades [Mullooly et al., 1993].
In the 1996/1997 season, viruses similar to A/Wu-
han/359/95(H3N2) (“Wuhan”) were responsible for
moderately severe influenza epidemics in the Northern
Hemisphere. As early as February 1996, the WHO fore-
saw the circulation of this variant and recommended
the inclusion of a Wuhan-like virus component in the
vaccine for the 1996/1997 season. This recommenda-
tion was repeated logically for the 1997/1998 season on
the basis of data available in February 1997. In June
1997, however, a new variant of influenza virus sub-
type A(H3N2)—represented by prototype strain A/Syd-
ney/5/97 (“Sydney”)—emerged in Australia and New
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Zealand, where it gave rise to extensive epidemics
[Anonymous, 1998]. This same variant was the major
cause of the epidemics in the Northern Hemisphere
during the early months of 1998, together with spo-
radic circulation of Wuhan-like strains [Anonymous,
1998]. Although the epidemic was described as mild,
the Netherlands Central Bureau of Statistics calcu-
lated an excess mortality of 1,400 for the Netherlands
in the period from March to April 1998 [Prins, 1998].
This coincided with an influenza epidemic that lasted
from mid-February until mid-April. In February 1998,
the WHO recommended the inclusion of a Sydney-like
strain in the influenza vaccine for the 1998/1999 sea-
son [Anonymous, 1998]. In the present study, the
match between the Wuhan-like vaccine strain and the
1997/1998 Wuhan-like and Sydney-like field isolates
was investigated by comparing the antibody responses
induced in ferrets. Moreover, in order to assess the ac-
tual efficacy of the influenza vaccine used in the 1997/
1998 season, the antibody responses of human influ-
enza vaccinees to these viruses also were measured.
MATERIALS AND METHODS
Antigens
The high-growth influenza A(H3N2) virus strain
RESVIR-9 was used for the 1997/1998 vaccine which
was administered to the participants of the present
study. It was similar to the epidemic WHO reference
strain A/Wuhan/359/95 and is therefore called “Wuhan
vaccine” in this article. For the 1998/1999 vaccine, the
high-growth influenza A(H3N2) virus strain IVR-108
was used. This strain was similar to the epidemic WHO
reference strain A/Sydney/5/97 and is called “Sydney
vaccine.” Strains A/Netherlands/300/97 (“Sydney
field”) and A/Netherlands/005/98 (“Wuhan field”) were
chosen as representative of the Sydney-like and the
Wuhan-like field strains, respectively, of the 1997/1998
epidemic.
Serum Samples
Three specific ferret antisera were prepared against
the Wuhan vaccine and one each against the Sydney
vaccine, Sydney field, and Wuhan field. The animals
were bled 2 weeks after intranasal infection with the
respective strains. The serum samples from vaccinees
used in the present study were obtained in the course of
three previous vaccination studies, each comprising 48
individuals. The first study group included healthy
adults aged 19 to 57 years (median age, 28 years), the
second group were free-dwelling elderly individuals
aged 60 to 77 years (median age, 65 years), and the
third group was made up of elderly persons living in
nursing homes who were aged 61 to 99 years (median
age, 82 years). All 144 individuals had been vaccinated
with one dose of a standard commercial trivalent influ-
enza subunit vaccine manufactured by Solvay Pharma-
ceuticals (Weesp, The Netherlands), containing 15 mg
hemagglutinin of each component. The vaccine con-
tained RESVIR-9 as the H3N2 component.
The first and second study groups were vaccinated
with batch L-0202 in July 1997 and the third group
with batch K-0302 in December 1996. In the first study
group, four participants also had been vaccinated in
1982, 1987, 1991, and 1991, respectively. None of the
participants had suffered an influenza-like illness in
the year before vaccination. Among the second study
group, two participants had been vaccinated in 1987
and 1991, respectively. Two other subjects of this group
had experienced an influenza-like illness in the year
before vaccination, in January 1996 and May 1997, re-
spectively. No data for histories of vaccination or influ-
enza-like illness were available for the participants of
the third study group. A blood sample was taken from
each vaccinee just before vaccination and 15 (study
groups 1 and 2) or 21–23 days (group 3) later.
In a linear regression model using the postvaccina-
tion titer as a dependent variable and prevaccination
titers, age, and study group as independent variables,
prevaccination titers and age, but not the study group,
proved to influence significantly the postvaccination ti-
ters. Therefore, in the present article the data are pro-
vided for three age classes (19–59, 60–74, and 75–99
years of age) rather than for the three study groups.
The absence of an effect of the study group in the linear
regression analysis also shows that the differences be-
tween the various study groups in the time of vaccina-
tion and in the batch of vaccine used did not influence
significantly the results of the study.
Hemagglutination Inhibition Assays and
Statistical Analysis
HI assays were carried out essentially as described
by Masurel et al. [1981]. All sera were titrated twice
against the four antigens listed in Table I. HI titers
were expressed as the reciprocals of the highest serum
dilution that completely inhibited hemagglutination by
four hemagglutination units of the test antigen. If no
HI was observed (titer lower than 20), the titer was
TABLE I. Antigens Used in the HI Titrations
Influence virus strain Name
Medium in
which isolated
and grown
RESVIR-9,
A/Wuhan/359/95-like
reassortant, 1997/1998
vaccine
Wuhan vaccine Embryonated
fowl eggs
A/Netherlands/005/98,
A/Wuhan/359/95-like
Wuhan field MDCK cell
culture
A/Netherlands/300/97,
A/Sydney/5/97-like
Sydney field MDCK cell
culture
IVR-108,
A/Sydney/5/97-like
reassortant, 1998/1999
vaccine
Sydney vaccine Embryonated
fowl eggs
HI, hemagglutination inhibition; MDCK, Madin Darby Canine Kid-
ney.
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arbitrarily recorded as 10 for calculation. The loga-
rithms of the pre- and postvaccination titers were con-
firmed to be normally distributed by the Kolmogorov –
Smirnov KS Goodness of Fit Test for Normal Distribu-
tion (SPSS for Windows 5.0). Comparisons between dif-
ferent viruses within a given age class were made us-
ing the paired t test (titers) and the McNemar x2 test
(proportions). Comparisons between age classes were
made using one-way ANOVA (titers) and the Pearson
x2 test (proportion). Differences between test results
were regarded as significant when P was < 0.05. Con-
fidence intervals were calculated using the Confidence
Interval Analysis software (version 1.0, 1989; S. B.
Gardner, P. D. Winter, and M. J. Gardner, distributed
by the British Medical Journal, London). The “50% pro-
tective threshold” of HI antibodies was set at 40 ($ 40
being considered protective), in accordance with usual
practice [Arden et al., 1986].
RESULTS
Ferret Antisera
The three ferret antisera raised against the Wuhan
vaccine showed HI titers against the Wuhan field that
were only two- to fourfold lower than the HI titers
against the Wuhan vaccine (Table II). However, HI ti-
ters of these antisera measured against the Sydney-
like field strains, which were the major cause of the
1997/1998 epidemic [Anonymous, 1998] and which
were represented by the Sydney field in the present
study, were eight- to 32-fold lower than those mea-
sured against the Wuhan vaccine. The HI data ob-
tained with ferret antisera raised against the two Syd-
ney-like viruses confirmed the major antigenic
difference between the Wuhan- and Sydney-like
strains.
Serum Samples From Vaccinees
The homologous serum HI antibody responses to the
Wuhan vaccine and the response to the Wuhan field
varied from strong in young people to fair in middle-
aged persons to moderate in the older age class (Table
III and Fig. 1). The responses to the Sydney field were
7.2-, 6.2-, and 11.2-fold, respectively, lower than the
responses to the Wuhan vaccine. In each of the three
cases, the differences between the titers to the two vi-
ruses are statistically significant. Moreover, the differ-
ences among the three mentioned quotients are statis-
tically significant (Table III). For the three age classes,
the percentages of vaccinees showing a “protective” HI
titer of $ 40 after vaccination were 100%, 93%, and
93%, respectively, against the Wuhan vaccine and 88%,
48%, and 22%, respectively, against Sydney field (Fig.
2). A better evaluation of the performance of the vac-
cines is obtained when the results of vaccination are
calculated only for those vaccinees who had prevacci-
nation titers of < 40. In the present study, the data
obtained in this way are roughly similar to the data for
all vaccinees (Table IV). The greatest difference was in
the oldest age class: only 16% of the subjects with pre-
vaccination HI titers of < 40 acquired a protective an-
tibody level.
DISCUSSION
In the 1997/1998 season, there was a mismatch be-
tween the H3N2 influenza vaccine component (Wuhan
vaccine) and the major epidemic H3N2 strain (Sydney
field). In the present study, sera were used from ferrets
after infection with various influenza virus strains and
from humans under 60 years of age, free-dwelling el-
TABLE III. Postvaccination Geometric Mean Titers Against the Wuhan
Vaccine and Sydney Field and Their Quotient*
Age class N
Antigens used in the HI titrations
Wuhan vaccine Sydney field Wv/Sf
19–59 yr 48 794 (592–1,066) 111 (78–156) 7.2 (5.9–8.8)
60–74 yr 56 255 (186–351) 42 (29–61) 6.1 (4.6–8.1)
75–99 yr 40 196 (137–426) 18 (13–42) 11.2 (8.5–14.8)
P (one-way
ANOVA) #0.001 #0.001 0.005
HI, hemagglutination inhibition; Wv/Sf, post-vaccination geometric mean titer (post-GMT)
against Wuhan vaccine/post-GMT against Sydney field.
*The 95% confidence intervals are given in parentheses.
TABLE II. Cross-reactivities of the Antigens Used in HI Assays With Ferret Antisera
Influenza
virus strain
Postinfection HI titers of ferret antisera againsta
Wuhan vaccine (three antisera) Wuhan field Sydney field Sydney vaccine
Wuhan vaccine 640 1,280 1,280 1,280 40 80
Wuhan field 320 320 320 1,280 80 80
Sydney field 80 160 40 320 2,560 5,120
Sydney vaccine 80 80 <20 80 2,560 5,120
HI, hemagglutination inhibition.
aHomologous titers are underlined and set in bold type.
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Fig. 1. Postvaccination geometric mean titer
on a log2 scale of serum samples from individuals
vaccinated with Wuhan vaccine, according to
three age classes. The vertical bars indicate the
95% confidence intervals.
Fig. 2. Proportions of subjects with postvacci-
nation titers of 40 or higher, according to three
age classes. The vertical bars indicate the 95%
confidence intervals.
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derly, and residents of nursing homes before and after
vaccination with the influenza vaccine for the 1997/
1998 season. The mean difference between the HI ti-
ters to the Wuhan vaccine and the Sydney field proved
to be eight- to 32-fold using ferret antisera (Table II)
and about six- to 11-fold using sera from human vac-
cinees (Table III). These observations are in line with
preliminary results published by the WHO for adults
and elderly vaccinated with the Wuhan vaccine
[Anonymous, 1998]. The results show that homologous
and heterologous postvaccination geometric mean titer
(post-GMT), as well as the percentage of subjects with
postvaccination titers $ 40, declined with increasing
age (Figs. 1 and 2).
In particular, the mismatch affected the immune re-
sponse to influenza vaccination in the 75- to 99-year-
old participants. In these subjects, the vaccine-induced
antibodies not only had a low titer to Wuhan vaccine
but also proved to be significantly less cross-reactive to
the Sydney field than the vaccine-induced antibodies in
the two younger age classes (11-fold versus six- to
seven-fold differences in post-GMT to the Wuhan vac-
cine and the Sydney field, respectively; Table III). In
the study group of nursing home residents, vaccine-
induced antibodies were significantly less cross-
reactive than those in the adults under 60 years of age
and the free-dwelling elderly participants over the age
of 60 years (10-fold versus seven- and sixfold differ-
ences in post-GMT to the Wuhan vaccine and the Syd-
ney field, respectively; P 4 0.014). A comparison of the
results from nursing home residents with those from
free-dwelling elderly in the same age range (61–77
years of age), however, did not elicit a statistically sig-
nificant difference in the immune response (data not
shown). Apparently, the lower cross-reactivity found in
the nursing home residents can be ascribed to the effect
of increasing age. This observed age effect is in line
with the findings of previous studies that suggest that
senescence, in particular, leads to an impaired ability
to respond to newly emerging influenza virus epitopes
(in this study the epitopes present in the Wuhan- and
Sydney-like strains but not in earlier vaccine or epi-
demic strains), a phenomenon that may be related to
the “original antigenic sin” [Beyer et al., 1989; McEl-
haney et al., 1993; Powers and Belshe, 1994].
The proportions of vaccinees who acquired at least
the presumed 50% protective antibody titer of 40
against Sydney field were 87%, 47%, and 16%, respec-
tively, for the three age classes (Table IV). For the el-
derly, especially for older residents of nursing homes,
who form a major target for protection against compli-
cations and death by influenza [Betts, 1995], this ob-
servation implies insufficient induction of immunity to
the Sydney-like viruses. The data show that the results
from antigenic analyses with ferret antisera were in
good agreement with those obtained using sera from
vaccinees. The results support the effectiveness of the
WHO worldwide surveillance system, which, for prac-
tical reasons, is largely based on the use of animal an-
tisera. Furthermore, they confirm that vaccination tri-
als in adults less than 60 years of age should be
considered at face value, bearing in mind that the an-
tibody response may be less pronounced in the elderly.
The success of the WHO worldwide influenza surveil-
lance program is illustrated by the rare occurrence of
antigenic mismatches, such as that described in the
present study. When ongoing surveillance data indi-
cate such a mismatch, the WHO should consider a
change from its original recommendation (despite the
serious practical implications) and recommend the pro-
duction of a vaccine based on the newly emerged epi-
demic strain. This policy was adopted in 1986, when
the A/Taiwan/86 (H1N1) strain appeared in August of
that year [Anonymous, 1986].
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